Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free HKPD Stock Alerts

Hong Kong Pharma Digital Technology (HKPD) Competitors

Hong Kong Pharma Digital Technology logo
$0.11 +0.01 (+7.72%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$0.10 -0.01 (-7.08%)
As of 06:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HKPD vs. RDGT, MCK, COR, CAH, and HSIC

Should you buy Hong Kong Pharma Digital Technology stock or one of its competitors? Hong Kong Pharma Digital Technology's main competitors and comparable companies include Ridgetech (RDGT), McKesson (MCK), Cencora (COR), Cardinal Health (CAH), and Henry Schein (HSIC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare distributors" industry.

How does Hong Kong Pharma Digital Technology compare to Ridgetech?

Ridgetech (NASDAQ:RDGT) and Hong Kong Pharma Digital Technology (NASDAQ:HKPD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Hong Kong Pharma Digital Technology has lower revenue, but higher earnings than Ridgetech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ridgetech$132.16M0.02-$1.25MN/AN/A
Hong Kong Pharma Digital Technology$13.43M0.14-$1.14MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ridgetech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Hong Kong Pharma Digital Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Hong Kong Pharma Digital Technology had 1 more articles in the media than Ridgetech. MarketBeat recorded 2 mentions for Hong Kong Pharma Digital Technology and 1 mentions for Ridgetech. Hong Kong Pharma Digital Technology's average media sentiment score of 1.39 beat Ridgetech's score of 1.13 indicating that Hong Kong Pharma Digital Technology is being referred to more favorably in the news media.

Company Overall Sentiment
Ridgetech Positive
Hong Kong Pharma Digital Technology Positive

Ridgetech has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, Hong Kong Pharma Digital Technology has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market.

45.3% of Ridgetech shares are held by institutional investors. 22.6% of Ridgetech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
RidgetechN/A N/A N/A
Hong Kong Pharma Digital Technology N/A N/A N/A

Summary

Hong Kong Pharma Digital Technology beats Ridgetech on 5 of the 8 factors compared between the two stocks.

How does Hong Kong Pharma Digital Technology compare to McKesson?

McKesson (NYSE:MCK) and Hong Kong Pharma Digital Technology (NASDAQ:HKPD) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

85.1% of McKesson shares are held by institutional investors. 0.1% of McKesson shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, McKesson had 19 more articles in the media than Hong Kong Pharma Digital Technology. MarketBeat recorded 21 mentions for McKesson and 2 mentions for Hong Kong Pharma Digital Technology. Hong Kong Pharma Digital Technology's average media sentiment score of 1.39 beat McKesson's score of 0.71 indicating that Hong Kong Pharma Digital Technology is being referred to more favorably in the news media.

Company Overall Sentiment
McKesson Positive
Hong Kong Pharma Digital Technology Positive

McKesson has higher revenue and earnings than Hong Kong Pharma Digital Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$403.43B0.28$4.76B$37.3726.15
Hong Kong Pharma Digital Technology$13.43M0.14-$1.14MN/AN/A

McKesson has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Hong Kong Pharma Digital Technology has a beta of 2.57, suggesting that its stock price is 157% more volatile than the broader market.

McKesson has a net margin of 1.12% compared to Hong Kong Pharma Digital Technology's net margin of 0.00%. Hong Kong Pharma Digital Technology's return on equity of 0.00% beat McKesson's return on equity.

Company Net Margins Return on Equity Return on Assets
McKesson1.12% -253.21% 5.90%
Hong Kong Pharma Digital Technology N/A N/A N/A

McKesson currently has a consensus price target of $983.29, suggesting a potential upside of 0.61%. Given McKesson's stronger consensus rating and higher possible upside, research analysts clearly believe McKesson is more favorable than Hong Kong Pharma Digital Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
McKesson
0 Sell rating(s)
4 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.79
Hong Kong Pharma Digital Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

McKesson beats Hong Kong Pharma Digital Technology on 11 of the 14 factors compared between the two stocks.

How does Hong Kong Pharma Digital Technology compare to Cencora?

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) and Cencora (NYSE:COR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Cencora has a consensus target price of $365.69, suggesting a potential upside of 8.88%. Given Cencora's stronger consensus rating and higher probable upside, analysts plainly believe Cencora is more favorable than Hong Kong Pharma Digital Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hong Kong Pharma Digital Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cencora
0 Sell rating(s)
4 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.78

In the previous week, Cencora had 20 more articles in the media than Hong Kong Pharma Digital Technology. MarketBeat recorded 22 mentions for Cencora and 2 mentions for Hong Kong Pharma Digital Technology. Hong Kong Pharma Digital Technology's average media sentiment score of 1.39 beat Cencora's score of 0.74 indicating that Hong Kong Pharma Digital Technology is being referred to more favorably in the media.

Company Overall Sentiment
Hong Kong Pharma Digital Technology Positive
Cencora Positive

Cencora has a net margin of 0.79% compared to Hong Kong Pharma Digital Technology's net margin of 0.00%. Cencora's return on equity of 125.45% beat Hong Kong Pharma Digital Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Hong Kong Pharma Digital TechnologyN/A N/A N/A
Cencora 0.79%125.45%4.18%

97.5% of Cencora shares are owned by institutional investors. 0.4% of Cencora shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cencora has higher revenue and earnings than Hong Kong Pharma Digital Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hong Kong Pharma Digital Technology$13.43M0.14-$1.14MN/AN/A
Cencora$321.33B0.20$1.55B$13.4624.95

Hong Kong Pharma Digital Technology has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market. Comparatively, Cencora has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Summary

Cencora beats Hong Kong Pharma Digital Technology on 12 of the 14 factors compared between the two stocks.

How does Hong Kong Pharma Digital Technology compare to Cardinal Health?

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) and Cardinal Health (NYSE:CAH) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Hong Kong Pharma Digital Technology has a beta of 2.57, indicating that its share price is 157% more volatile than the broader market. Comparatively, Cardinal Health has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Cardinal Health has a consensus price target of $266.56, indicating a potential upside of 7.78%. Given Cardinal Health's stronger consensus rating and higher probable upside, analysts clearly believe Cardinal Health is more favorable than Hong Kong Pharma Digital Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hong Kong Pharma Digital Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cardinal Health
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84

In the previous week, Cardinal Health had 8 more articles in the media than Hong Kong Pharma Digital Technology. MarketBeat recorded 10 mentions for Cardinal Health and 2 mentions for Hong Kong Pharma Digital Technology. Hong Kong Pharma Digital Technology's average media sentiment score of 1.39 beat Cardinal Health's score of 0.91 indicating that Hong Kong Pharma Digital Technology is being referred to more favorably in the media.

Company Overall Sentiment
Hong Kong Pharma Digital Technology Positive
Cardinal Health Positive

Cardinal Health has higher revenue and earnings than Hong Kong Pharma Digital Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hong Kong Pharma Digital Technology$13.43M0.14-$1.14MN/AN/A
Cardinal Health$254.25B0.23$1.71B$7.2334.21

87.2% of Cardinal Health shares are held by institutional investors. 0.1% of Cardinal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cardinal Health has a net margin of 0.67% compared to Hong Kong Pharma Digital Technology's net margin of 0.00%. Hong Kong Pharma Digital Technology's return on equity of 0.00% beat Cardinal Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Hong Kong Pharma Digital TechnologyN/A N/A N/A
Cardinal Health 0.67%-98.53%4.69%

Summary

Cardinal Health beats Hong Kong Pharma Digital Technology on 11 of the 14 factors compared between the two stocks.

How does Hong Kong Pharma Digital Technology compare to Henry Schein?

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) and Henry Schein (NASDAQ:HSIC) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Henry Schein has higher revenue and earnings than Hong Kong Pharma Digital Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hong Kong Pharma Digital Technology$13.43M0.14-$1.14MN/AN/A
Henry Schein$13.60B0.70$398M$3.4324.94

Henry Schein has a net margin of 2.96% compared to Hong Kong Pharma Digital Technology's net margin of 0.00%. Henry Schein's return on equity of 15.97% beat Hong Kong Pharma Digital Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Hong Kong Pharma Digital TechnologyN/A N/A N/A
Henry Schein 2.96%15.97%5.56%

96.6% of Henry Schein shares are owned by institutional investors. 0.9% of Henry Schein shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Henry Schein has a consensus price target of $93.27, suggesting a potential upside of 9.01%. Given Henry Schein's stronger consensus rating and higher probable upside, analysts clearly believe Henry Schein is more favorable than Hong Kong Pharma Digital Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hong Kong Pharma Digital Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Henry Schein
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.53

Hong Kong Pharma Digital Technology has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market. Comparatively, Henry Schein has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

In the previous week, Henry Schein had 7 more articles in the media than Hong Kong Pharma Digital Technology. MarketBeat recorded 9 mentions for Henry Schein and 2 mentions for Hong Kong Pharma Digital Technology. Hong Kong Pharma Digital Technology's average media sentiment score of 1.39 beat Henry Schein's score of 0.69 indicating that Hong Kong Pharma Digital Technology is being referred to more favorably in the media.

Company Overall Sentiment
Hong Kong Pharma Digital Technology Positive
Henry Schein Positive

Summary

Henry Schein beats Hong Kong Pharma Digital Technology on 12 of the 14 factors compared between the two stocks.

Get Hong Kong Pharma Digital Technology News Delivered to You Automatically

Sign up to receive the latest news and ratings for HKPD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HKPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HKPD vs. The Competition

Export
MetricHong Kong Pharma Digital TechnologyHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.72M$10.03B$7.18B$13.18B
Dividend YieldN/A2.61%2.52%19.59%
P/E RatioN/A29.94215.3319.57
Price / Sales0.144.70571.6381.29
Price / CashN/A115.8876.6852.75
Price / Book0.195.1410.375.92
Net Income-$1.14M$315.68M$3.50B$380.90M
7 Day Performance12.10%-0.01%-3.49%-3.90%
1 Month Performance-0.26%-4.33%-7.76%-6.42%
1 Year Performance-90.96%9.30%0.82%-6.01%

Hong Kong Pharma Digital Technology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HKPD
Hong Kong Pharma Digital Technology
1.4202 of 5 stars		$0.11
+7.7%		N/A-91.0%$1.72M$13.43MN/A27
RDGT
Ridgetech
0.5832 of 5 stars		$0.87
flat		N/A-99.6%$3.17M$132.16MN/A980
MCK
McKesson
4.3705 of 5 stars		$903.14
+0.1%		$973.44
+7.8%		+25.0%$105.30B$403.43B24.1743,000
COR
Cencora
4.677 of 5 stars		$309.75
+0.2%		$370.85
+19.7%		+5.7%$59.11B$321.33B23.0151,000
CAH
Cardinal Health
4.55 of 5 stars		$228.78
+0.2%		$266.56
+16.5%		+60.5%$52.98B$254.25B31.6463,900

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HKPD) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
100% overnight gains?
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel